| Basics |
Intellia Therapeutics, Inc.
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
|
| IPO Date: |
May 6, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$741.66M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.15 | 3.18%
|
| Avg Daily Range (30 D): |
$0.29 | 3.51%
|
| Avg Daily Range (90 D): |
$0.35 | 4.01%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.98M |
| Avg Daily Volume (30 D): |
4.21M |
| Avg Daily Volume (90 D): |
3.45M |
| Trade Size |
| Avg Trade Size (Sh.): |
72 |
| Avg Trade Size (Sh.) (30 D): |
117 |
| Avg Trade Size (Sh.) (90 D): |
102 |
| Institutional Trades |
| Total Inst.Trades: |
4,276 |
| Avg Inst. Trade: |
$3M |
| Avg Inst. Trade (30 D): |
$2.08M |
| Avg Inst. Trade (90 D): |
$2.19M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.85M |
| Avg Closing Trade (30 D): |
$2.71M |
| Avg Closing Trade (90 D): |
$2.85M |
| Avg Closing Volume: |
137.97K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-1.1
|
$-1.34
|
|
Diluted EPS
|
|
$-1.1
|
$-1.34
|
|
Revenue
|
$
|
$ 16.63M
|
$ 9.11M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -114.33M
|
$ -135.71M
|
|
Operating Income / Loss
|
$
|
$ -120.81M
|
$ -144.77M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ M
|
$ -10.35M
|
|
PE Ratio
|
|
|
|
|
|
|
